BiotechTube

Palynziq

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Phenylketonurias

Conditions

Phenylketonurias

Trial Timeline

Oct 8, 2019 → Dec 1, 2028

NCT ID
NCT04404530

About Palynziq

Palynziq is a pre-clinical stage product being developed by BioMarin Pharmaceutical for Phenylketonurias. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04404530. Target conditions include Phenylketonurias.

What happened to similar drugs?

0 of 3 similar drugs in Phenylketonurias were approved

Approved (0) Terminated (0) Active (3)
🔄sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
🔄sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
🔄Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
3
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04404530Pre-clinicalRecruiting

Competing Products

7 competing products in Phenylketonurias

See all competitors
ProductCompanyStageHype Score
SapropterinBioMarin PharmaceuticalPre-clinical
23
PegvaliaseBioMarin PharmaceuticalPre-clinical
23
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 2
32
sapropterin dihydrochlorideBioMarin PharmaceuticalPhase 3
37
sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterinBioMarin PharmaceuticalPhase 3
37
Pegvaliase-PqpzBioMarin PharmaceuticalPre-clinical
23
Sapropterin Dihydrochloride + PlaceboBioMarin PharmaceuticalPhase 3
37